Home › Funds › Kooman & Associates › GSK
Kooman & Associates position in GSK
GSK PLC · Health Care
Kooman & Associates reported holding 5,741 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$277K, representing 0.07% of its reported portfolio and ranking #49 among its reported holdings. Kooman & Associates has disclosed GSK holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Kooman & Associates's GSK position evolved
Kooman & Associates first disclosed a stake in GSK in Q3 2023 at 6,229 shares (US$226K). The position peaked in Q4 2025 at 7,254 shares, worth US$356K. Across 12 filings, Kooman & Associates increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 5,741 shares valued at US$277K — an increase of 49 shares quarter over quarter.. Notable position changes include a 38% increase in Q2 2025 (shares rose 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 6.23K | $225.80K | New |
| Q4 2023 | 6.27K | $232.33K | Add |
| Q1 2024 | 6.23K | $267.04K | Reduce |
| Q2 2024 | 6.23K | $239.82K | Hold |
| Q3 2024 | 6.23K | $254.64K | Hold |
| Q1 2025 | 5.69K | $220.51K | New |
| Q2 2025 | 7.83K | $300.83K | Add |
| Q3 2025 | 7.82K | $337.30K | Hold |
| Q4 2025 | 7.25K | $355.74K | Reduce |
| Q1 2026 | 5.69K | $314.14K | Reduce |
| Q2 2026 | 5.69K | $298.38K | Hold |
| Q3 2026 | 5.74K | $276.54K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 20 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.19M sh · $1.21B · Q3 2026
- JTC Employer Solutions Trustee Ltd 8.08M sh · $389.17M · Q3 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.92M sh · $188.73M · Q3 2026
- EQUITY INVESTMENT CORP 3.56M sh · $171.52M · Q3 2026
More on Kooman & Associates
FAQ
How long has Kooman & Associates held GSK?
Kooman & Associates has disclosed GSK holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
What is Kooman & Associates's current position in GSK?
As of Q3 2026, Kooman & Associates holds 5.74K shares of GSK (GSK PLC), valued at $276.54K, representing 0.07% of its reported portfolio and ranking #49.
Has Kooman & Associates been buying or selling GSK?
In the latest 13F filing (Q3 2026), Kooman & Associates increased its position in GSK. The position peaked in Q4 2025 at 7.25K shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.